SoftBank paid $350m for a 30% stake in the satellite internet system developer, which has emerged from bankruptcy, while Hughes Network Systems supplied the other $50m.

Kaiser Foundation Hospitals and Medpace took part in a round that will support phase 3 trials for the startup's lead cardiometabolic disease drug candidate.

Existing investor Scania co-led a series D round in which the trucking services platform developer achieved a valuation above $1bn.

Illumina Ventures and AV8 Ventures returned for a series A round that will push the startup's liquid biopsy technology towards the clinical trial stage.

Lundbeck and Novo were among the participants in the immuno-oncology drug developer's series B round having backed its series A four years ago.

The GV-backed market intelligence platform developer has pushed its total funding past $150m in a series E round led by WestCap Group.

Tencent led an $83.9m round for the insurance technology developer, which counts Axel Springer and ProSiebenSat.1 among its earlier investors.

The Minth Group, Zoll Medical and Abiomed-backed medical device developer has raised at least $217m in total after closing additional series D funding.

The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.

Pfizer's Breakthrough Growth Initiative has backed the PureTech microbiome spinoff, which will use the cash to finance phase 2 tests of its lead IBD drug candidate.